BVS

Bioventus Inc.

Price

$14.68

return (12m)

100.55% Logo

p/e

17.47

p/bv

3.43

DIVIDEND YIELD

0.00%
graph

BVS price

Select period
Select period
Bioventus
If you had invested
If you had invested
exposure
years ago
7 days
30 days
6 months
YTD
1 year
5 years
10 years
15 years
ago, you would now have *
ago, you would now have:
*
*This calculation reflects price variation only.

Return on Investment BVS

1 month
3 months
1 year
2 years
5 years
10 years
return
1 month
24.30%
3 months
54.61%
1 year
100.55%
2 years
83.50%
5 years
-7.61%
10 years
0.00%
Fundamental indicators

Fundamentals BVS

Check the fundamentals of Bioventus shares.

Valuation

P/E
17.47
Sector -2.19
Industry 1.21
P/BV
3.43
Sector 2.22
Industry 2.11
P/Revenue (PSR)
1.63
Sector 2.01
Industry 0.78
EV/EBITDA
37.98
Sector -17.81
Industry -25.30
EV/EBIT
59.42
Sector -26.72
Industry -18.04
P/EBITDA
9.17
Sector 0.36
Industry 0.18
P/EBIT
16.26
Sector -3.34
Industry 1.26
P/Total Assets
1.41
Sector 1.23
Industry 0.86
P/Net Current Assets
-6.87
Sector -27.35
Industry -12.37
P/Working Capital
9.05
Sector -4.54
Industry -49.48
EPS
0.80
Sector -0.87
Industry -0.55
BVPS
4.08
Sector 3.80
Industry 5.36

Efficiency

Gross Margin
68.65%
Sector 43.36%
Industry 31.53%
EBITDA Margin
19.79%
Sector -323.65%
Industry -73.39%
EBIT Margin
12.65%
Sector -194.57%
Industry -11.94%
Operating Margin
10.41%
Sector -24.37%
Industry -9.87%
Net Profit Margins
9.36%
Sector -28.88%
Industry -19.76%
Asset Turnover
0.23
Sector 0.12
Industry 0.22

Profitability

ROE
19.63%
Sector -33.82%
Industry -37.56%
ROA
8.09%
Sector -29.63%
Industry -17.56%
ROIC
14.24%
Sector -431.16%
Industry -111.59%

Dividends

Dividend yield
0.00%
Sector -
Industry -
Payout
0.00%
Sector -
Industry -

Debt

Current Ratio
1.69
Sector 1.84
Industry 1.14
Net Debt / EBITDA
6.60
Sector -1.47
Industry -31.86
Net Debt / EBIT
10.33
Sector -1.32
Industry 2.06
Net Debt / Equity
0.72
Sector -0.35
Industry 0.14
Gross Debt / Equity
0.83
Sector 0.14
Industry 0.51
Equity/Assets
0.41
Sector 0.42
Industry 0.25
Liabilities/Assets
0.59
Sector 0.46
Industry 0.46

Growth

5Y Revenue CAGR
6.19%
Sector -
Industry -
5Y Earnings CAGR
22.95%
Sector -
Industry -
RETORNO DO INVESTIMENTO

FAIR VALUE OF Bioventus ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$14.68

Fair Value

$8.57

Upside Return potential.

-41.62%
Because it considers equity value in its calculation, this formula may not work well for technology companies.
This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.
Histórico de indicadores fundamentalistas

Fundamentals BVS

Buy And Hold Investor Checklist

Bioventus Buy And Hold Investor Checklist

COMPARING BVS WITH OTHER STOCK

graph

Stock vs Indice Comparison Tool

If you had invested
If you had invested
years ago
2 years
5 years
10 years
ago, you would now have *
ago, you would now have:
*
*This calculation reflects price variation only.
Price

BVS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT

Logo Bioventus

Bioventus Inc.

Average Investor10 user rating

4.0 (0 people)

United States

United States

11 years

Founded: 2015

2021

Time since IPO - 5 years

700

Employees

Market cap

$951.32 million

$951.32 million

Net worth

$277.41 million

$277,410,000.00

Assets

$673.35 million

$673,350,000.00

Total Shares Outstanding

68.00 million

68,000,000

Average Daily Trading Volume

$746.28 Thousand

$746,280.22

Shares

receitas e lucros

BVS revenue and profits

graph

PROFIT X PRICE BVS

Financials

Financial Results BVS

DRAG THE FRAME TO SEE MORE DATA
Financials

BVS cash flow

DRAG THE FRAME TO SEE MORE DATA
Ativos e Passivos

Asset, Revenue and Profit Growth - BVS

Pontos Relevantes

BVS balance sheet

DRAG THE FRAME TO SEE MORE DATA

Frequently Asked Questions

What is the price of Bioventus (BVS) today?

A cotação de Bioventus (BVS) hoje está em US$ 14.68, com uma variação de 100.55% em relação ao último ano. A cotação de Bioventus (BVS) iniciou o ano negociando na casa dos US$ 7.44 e hoje está em US$ 14.68. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Bioventus (BVS) e dados de ações do Ibovespa e mercados internacionais.

Quando Bioventus (BVS) paga dividendos?

Bioventus (BVS) não distribuiu dividendos no último ano.

Is Bioventus (BVS) a good investment?

Atualmente, Bioventus (BVS) está cotada a US$ 14.68, com um P/L de 17.47, representando um desvio de 346% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 100.55 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 100.55%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Bioventus (BVS) stock?

Investir em ações de Bioventus (BVS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Bioventus (BVS) yield today?

A rentabilidade de Bioventus (BVS) foi de 24.30% no último mês, 100.55% no último ano e -7.61% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Bioventus (BVS) hoje, o investimento total seria de US$ 1,468.00, com base na cotação atual de US$ 14.68.

Based on historical performance, the investment would have grown to approximately:

  • Em 1 ano: US$ 2,944.07
  • Em 5 anos: US$ 1,356.29
  • Em 10 anos: US$ 1,468.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.